21/11/2023 09:26

CSL Ltd (CSL) $257.62

CSL has been one of the sector losers through 2023, with “wonder weight loss drug” Ozempic weighing in the stock in October even though only ~8% of its earnings are exposed

Read more

07/11/2023 09:15

CSL Ltd (CSL) $248.22

CSL struggled through September & October on concerns around earnings in its Vifor nephrology and dialysis (kidney disease treatment) business impacted by the “Ozempic revolution”.

Read more

13/10/2023 09:46

CSL Ltd (CSL) $238.24

CSL grabbed the headlines for the wrong reasons on Thursday as the stock plunged over 6% as further damage was inflicted on the ASX Healthcare Sector by GLP-1’s (diabetes drug), ResMed has already illustrated over recent weeks the market appetite for uncertainty around this “wonder drug”. The market favourite plunged to 4-year lows, over -30% below its 2020 high, with around 8% of CSL’s earnings in its Vifor business’s nephrology and dialysis (kidney disease treatment) potentially impacted by Novo Nordisks study, which many see changing the global obesity problem.

Read more

12/10/2023 16:41

CSL Ltd (CSL) $238.24

CSL -6.3%: the GLP-1 troubles that have plagued ResMed (RMD) over the last month have also put pressure on the biopharma company, sending the stock to 4-year lows today. Novo Nordisk is currently trialling their GLP-1 drug on chronic kidney disease (CKD) and Type 2 Diabetes (T2D) with a 5-year study expected to be completed late next year.

Read more

12/09/2023 09:29

CSL Ltd (CSL) $268.57

CSL led the Healthcare Sector lower with many of its peers following suit including Ramsay Healthcare (RHC) and ResMed (RMD) that we hold in our Flagship Growth portfolio, we are deliberating switching our RMD position to CSL as markets become fixated on Ozempic’s cure to obesity and the impact this may have on sleep apnea treatments.

Read more

31/08/2023 09:40

CSL Ltd (CSL) $271.91

At MM we thought CSL’s report was ok this month with revenue growth guidance of 9-11% above consensus but the market’s reaction has been muted at best. We can see this stock re-rate back on the upside over the coming months supported by its position as a growth-oriented large cap pharma, especially as we see little near-term downside risk i.e. were keen buyers into dips under $260.

Read more

31/08/2023 09:37

The Bottom Line

We believe the Healthcare Sector is likely to enjoy some performance catch up over the coming months/quarters although there’s no clear trigger to say the moves yet commenced. Our main focus today is around actual holdings:

Read more

22/08/2023 09:33

CSL Ltd (CSL) $266.86

Blood plasma goliath CSL reported reasonably well early this month but it hasn’t been enough for the market which has sent the stock slightly lower, it doesn’t help that CSL  is very owned and loved on our fare shores after a decade of strong performance.

Read more

15/08/2023 17:09

CSL Limited (CSL) $272.80

CSL +3.73%: Strong today following a marginal beat in FY23 at the earnings line ($2.44bn v $2.19bn exp) as plasma collections were solid, volumes up 31% and now at record levels while the costs associated with collections fell.

Read more

27/07/2023 09:31

CSL Ltd (CSL) $262.86

CSL is a stock Australian investors love to love, no surprise really after its stellar performance over the last 15 years, but love is not generally helpful when it comes to investing. The issue with CSL for now, apart from everyone being bullish on the stock, is the guidance they provided for FY24 was a fair bit below the expectations of the market, with margins not recovering as strongly as many thought they would.

Read more